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In the year 1988, the practical approach to the patient wtth 
evolving myocardial infarction has been extensively up-  
dated. Much has heen learned about routine patien: manage- 
ment and many new issues have been raised. Intravenous 
thrombolytic therapy with streptokinase or  recombinant 
tissue-type plasminogen activator (n-PA), previously under 
investigation, has been approved for clinical use in the 
United States. Three new randomized trials ( l-3) of coro- 
nary angioplasty performed immediately after administration 
of tissue plasminogen activator have demonstrated the lack 
of need for emergency mechanical revascularization in the 
majority of patients. Surveys (4)  of physicians have demon- 
strated rapid acceptance and widespread use of thrombolytic 
intervention. It is estimated that more than 250,000 patients 
in the United States will receive a thrombolytic agent for 
acute myocardial infarction this year. The major goal of this 
supplement is to provide the cardiovascular practitioner with 
a review of the pertinent information to link together basic 
and clinical trial findings with present and future patient 
management practices. 
One of the fundamental reasons for this new era of 
reperfusion has been the completion of many well designed 
and executed randomized clinical trials. Perhaps in no other 
field of cardiology has there been such extensive clinical trial 
work as has taken place in myocardial reperfusion over the 
past 5 years. A landmark study is the Gruppo ltaliano per  lo 
Studio della Streptochinasi nell’lnfarto Miocardico (GISSI) 
trial, which was the first modern large scale trial that 
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demonstrated a survival advantage with high dose intrave- 
nous \treptokinase (5). Because new trials have largely been 
responsible for the major advances in this field, the first 
section of ihis supplement is devoted to this end. 
New clinical trials. In the first report, the International 
Studies of Infarct Survival (ISIS) group present their da!a 
from the largest reperfusion trial ever performed, in which 
> 17.ooO patients were randomly assigned to streptokinase or  
aspirin. their combination or  double placebo. The trial not 
only confirms the overall survival benefit of strep:okinase 
initially reported by GISSI, but also markedly extends their 
findings with respect to the additive effect of aspirin and the 
broad time window (to 24 h)  over which the mortality rate 
was reduced. Without question, the ISIS-2 study will be 
viewed as a pivotal demonstration of the powerful effect of 
reperfusion in the years ahead. 
Van de Werfand the European Cooperative Study Group 
review the recently completed rt-PA. placebo-controlled 
trial, in which the benefit of left ventricular function was 
confirmed and a very low mortality rate (~3%) was demon- 
strated in the treatment group. De Bono presents a concise 
summary and analysis of the European Cooperative Study 
Group’s trial of tissue plasmincgen ac:irator and immediate 
coronary angioplasty. Subsequently, we discuss the latest 
findings from the Thrombolysis and kngioplasty in Myocar- 
dial Infarction (TAMI) Study Group. Collectively, these data 
represent the most up to date information on new clinical 
trials of myocardial reperfusion. 
Practical aspects. In the second section, several practical 
issues are addressed. Mark et al. review the important 
decisions of triage in the emergency room of the community 
hospital and provide an in-depth discussion on the role of 
emergency coronary angiography. With all recent clinical 
reperfusion trials as a data base, Bates describes the patients 
with inferior wall myocardial infarction, which has been a 
“735.1097188/S3.50 
?A T”P”L AND CAUFF 
lNTROD”CTl”N 
JACC Vol 12. No h 
Deccmher 198s IIWA 
coni,oversial group as IO wl;;:hcr treatr.:ent is clearly indi- 
cated. The risk/benefit ratio of aggressive intervention is 
reviewed by Faxon. and a cost/benefit ana!ysis is presented 
by Steinberg et al. 
New directions. The finai section contams three reports 
that focus on new directions in reperfusion. The role of 
thrombclytic therapy in unstable angina pectoris has re-  
cen!ly been studied in small clinical trials. Suijapranata et 
al. of the Thoraxcenter present their experience with the 
combined use of intracoronary streptokinase and coronary 
angioplasty in these patients. A key adjunct to thrombolysis 
in the fulure will undoubtedly be antiplatelet therapy. Fuster 
et al. provide their insights on the role of antiplatelet agents 
after thrombolytic intervention. Finally, Braunwald pro-  
vides a summary of the progress that has been made m this 
field and the many important, residual unanswered questions 
that remain. 
We consider these I I reports IO be representative of the 
rapid progress that has been made in the field of myocardial 
reperfusion. We are grateful IO the Genentech Corporation 
for providing an educational grant IO support the supplement 
without input regarding subjects, authors or  editing. This has 
been an exciting time in cardiovascular medicine, especially 
in the current phase of widely applying these new therapeu- 
tic interventions. 
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